Cargando…

Combined Immune Therapy for the Treatment of Visceral Leishmaniasis

Chronic disease caused by infections, cancer or autoimmunity can result in profound immune suppression. Immunoregulatory networks are established to prevent tissue damage caused by inflammation. Although these immune checkpoints preserve tissue function, they allow pathogens and tumors to persist, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Faleiro, Rebecca J., Kumar, Rajiv, Bunn, Patrick T., Singh, Neetu, Chauhan, Shashi Bhushan, Sheel, Meru, Amante, Fiona H., Montes de Oca, Marcela, Edwards, Chelsea L., Ng, Susanna S., Best, Shannon E., Haque, Ashraful, Beattie, Lynette, Hafner, Louise M., Sacks, David, Nylen, Susanne, Sundar, Shyam, Engwerda, Christian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752322/
https://www.ncbi.nlm.nih.gov/pubmed/26872334
http://dx.doi.org/10.1371/journal.pntd.0004415
_version_ 1782415711410323456
author Faleiro, Rebecca J.
Kumar, Rajiv
Bunn, Patrick T.
Singh, Neetu
Chauhan, Shashi Bhushan
Sheel, Meru
Amante, Fiona H.
Montes de Oca, Marcela
Edwards, Chelsea L.
Ng, Susanna S.
Best, Shannon E.
Haque, Ashraful
Beattie, Lynette
Hafner, Louise M.
Sacks, David
Nylen, Susanne
Sundar, Shyam
Engwerda, Christian R.
author_facet Faleiro, Rebecca J.
Kumar, Rajiv
Bunn, Patrick T.
Singh, Neetu
Chauhan, Shashi Bhushan
Sheel, Meru
Amante, Fiona H.
Montes de Oca, Marcela
Edwards, Chelsea L.
Ng, Susanna S.
Best, Shannon E.
Haque, Ashraful
Beattie, Lynette
Hafner, Louise M.
Sacks, David
Nylen, Susanne
Sundar, Shyam
Engwerda, Christian R.
author_sort Faleiro, Rebecca J.
collection PubMed
description Chronic disease caused by infections, cancer or autoimmunity can result in profound immune suppression. Immunoregulatory networks are established to prevent tissue damage caused by inflammation. Although these immune checkpoints preserve tissue function, they allow pathogens and tumors to persist, and even expand. Immune checkpoint blockade has recently been successfully employed to treat cancer. This strategy modulates immunoregulatory mechanisms to allow host immune cells to kill or control tumors. However, the utility of this approach for controlling established infections has not been extensively investigated. Here, we examined the potential of modulating glucocorticoid-induced TNF receptor-related protein (GITR) on T cells to improve anti-parasitic immunity in blood and spleen tissue from visceral leishmaniasis (VL) patients infected with Leishmania donovani. We found little effect on parasite growth or parasite-specific IFNγ production. However, this treatment reversed the improved anti-parasitic immunity achieved by IL-10 signaling blockade. Further investigations using an experimental VL model caused by infection of C57BL/6 mice with L. donovani revealed that this negative effect was prominent in the liver, dependent on parasite burden and associated with an accumulation of Th1 cells expressing high levels of KLRG-1. Nevertheless, combined anti-IL-10 and anti-GITR mAb treatment could improve anti-parasitic immunity when used with sub-optimal doses of anti-parasitic drug. However, additional studies with VL patient samples indicated that targeting GITR had no overall benefit over IL-10 signaling blockade alone at improving anti-parasitic immune responses, even with drug treatment cover. These findings identify several important factors that influence the effectiveness of immune modulation, including parasite burden, target tissue and the use of anti-parasitic drug. Critically, these results also highlight potential negative effects of combining different immune modulation strategies.
format Online
Article
Text
id pubmed-4752322
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47523222016-02-26 Combined Immune Therapy for the Treatment of Visceral Leishmaniasis Faleiro, Rebecca J. Kumar, Rajiv Bunn, Patrick T. Singh, Neetu Chauhan, Shashi Bhushan Sheel, Meru Amante, Fiona H. Montes de Oca, Marcela Edwards, Chelsea L. Ng, Susanna S. Best, Shannon E. Haque, Ashraful Beattie, Lynette Hafner, Louise M. Sacks, David Nylen, Susanne Sundar, Shyam Engwerda, Christian R. PLoS Negl Trop Dis Research Article Chronic disease caused by infections, cancer or autoimmunity can result in profound immune suppression. Immunoregulatory networks are established to prevent tissue damage caused by inflammation. Although these immune checkpoints preserve tissue function, they allow pathogens and tumors to persist, and even expand. Immune checkpoint blockade has recently been successfully employed to treat cancer. This strategy modulates immunoregulatory mechanisms to allow host immune cells to kill or control tumors. However, the utility of this approach for controlling established infections has not been extensively investigated. Here, we examined the potential of modulating glucocorticoid-induced TNF receptor-related protein (GITR) on T cells to improve anti-parasitic immunity in blood and spleen tissue from visceral leishmaniasis (VL) patients infected with Leishmania donovani. We found little effect on parasite growth or parasite-specific IFNγ production. However, this treatment reversed the improved anti-parasitic immunity achieved by IL-10 signaling blockade. Further investigations using an experimental VL model caused by infection of C57BL/6 mice with L. donovani revealed that this negative effect was prominent in the liver, dependent on parasite burden and associated with an accumulation of Th1 cells expressing high levels of KLRG-1. Nevertheless, combined anti-IL-10 and anti-GITR mAb treatment could improve anti-parasitic immunity when used with sub-optimal doses of anti-parasitic drug. However, additional studies with VL patient samples indicated that targeting GITR had no overall benefit over IL-10 signaling blockade alone at improving anti-parasitic immune responses, even with drug treatment cover. These findings identify several important factors that influence the effectiveness of immune modulation, including parasite burden, target tissue and the use of anti-parasitic drug. Critically, these results also highlight potential negative effects of combining different immune modulation strategies. Public Library of Science 2016-02-12 /pmc/articles/PMC4752322/ /pubmed/26872334 http://dx.doi.org/10.1371/journal.pntd.0004415 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Faleiro, Rebecca J.
Kumar, Rajiv
Bunn, Patrick T.
Singh, Neetu
Chauhan, Shashi Bhushan
Sheel, Meru
Amante, Fiona H.
Montes de Oca, Marcela
Edwards, Chelsea L.
Ng, Susanna S.
Best, Shannon E.
Haque, Ashraful
Beattie, Lynette
Hafner, Louise M.
Sacks, David
Nylen, Susanne
Sundar, Shyam
Engwerda, Christian R.
Combined Immune Therapy for the Treatment of Visceral Leishmaniasis
title Combined Immune Therapy for the Treatment of Visceral Leishmaniasis
title_full Combined Immune Therapy for the Treatment of Visceral Leishmaniasis
title_fullStr Combined Immune Therapy for the Treatment of Visceral Leishmaniasis
title_full_unstemmed Combined Immune Therapy for the Treatment of Visceral Leishmaniasis
title_short Combined Immune Therapy for the Treatment of Visceral Leishmaniasis
title_sort combined immune therapy for the treatment of visceral leishmaniasis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752322/
https://www.ncbi.nlm.nih.gov/pubmed/26872334
http://dx.doi.org/10.1371/journal.pntd.0004415
work_keys_str_mv AT faleirorebeccaj combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT kumarrajiv combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT bunnpatrickt combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT singhneetu combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT chauhanshashibhushan combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT sheelmeru combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT amantefionah combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT montesdeocamarcela combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT edwardschelseal combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT ngsusannas combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT bestshannone combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT haqueashraful combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT beattielynette combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT hafnerlouisem combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT sacksdavid combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT nylensusanne combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT sundarshyam combinedimmunetherapyforthetreatmentofvisceralleishmaniasis
AT engwerdachristianr combinedimmunetherapyforthetreatmentofvisceralleishmaniasis